Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Talk about a hot take.
Press releases, Innova Medical Group, and Pasaca investment into Quantum just may be those indicators you are looking for on those "blue skies" ;)
QMC HealthID Partners with PopupRx; Deploys HealthID Solution Within Pharmacies Across Texas
[i]Partnership to also include Quantum Dot technology on prescription labels to combat drug counterfeiting
QMC HealthID, a wholly owned subsidiary of Quantum Materials Corp and supplier of management platforms and mobile apps that authenticate the process of infectious disease testing and reporting, today announced that it has partnered with PopupRx Inc. The licensing agreement will allow PopupRx’s 20-plus pharmacies to deploy the QMC HealthID™ app, giving these locations access to secure COVID-19 testing and reporting.
QMC HealthID™ is built with professional test administration and public health reporting in mind. When QMC HealthID™ becomes integrated with PopupRx’s growing network of pharmacies, each pharmacy will receive a professional digital platform that includes:
-Support for professional management and test administration.
-A convenient, easy to use privacy-first mobile app for pharmacy customers.
-Built-in tools to meet regulatory and business reporting requirements for infectious disease testing.
In addition, PopupRx and QMC intend to explore QMC’s proprietary anti-counterfeiting technology to combat medical product counterfeiting. The firms plan to combine QMC’s quantum dot labelling technology and platform with PopupRx’s supply chain experience and provide pharmacies with:
-An efficient and effective approach to limit counterfeit medical products.
-Enhanced digital capabilities to track products.
-Services that support the security of the distribution and the safety of health products.
PopupRx provides pharmacy services to independent pharmacies across Texas, providing prescriptions, testing and laboratory services to both urban and rural areas.
"We consider our partnership with QMC to be a game-changing event as we enter 2021. With over 1.7M packages stolen from the mail or lost each day in the US, we are excited about the prospect of creating a safe and secure way for pharmacies to Trace and Track essential and potentially life-saving prescription drug packages being delivered or shipped to patients within local communities across the United States and beyond," said David Vinson, CEO and Founder of EverydayRx (EverydayRx is a DBA of PopupRx).
QMC HealthID views this partnership as an example of how the pharmacy vertical can use quantum dots to securely track COVID-19 testing, actively combat prescription medication counterfeiting and help communities return to living.
"I am glad to announce this partnership with PopupRx. Our firms share a commitment to innovation and a common vision. We seek to improve health distribution networks, protect consumers, and promote access to quality health products and services," said Stephen B. Squires, CEO of Quantum Materials Corp. "We value the opportunity to integrate QMC HealthID™ into the EverydayRX network of pharmacies and to join forces against fake and counterfeit health products."
About Quantum Materials Corp
At Quantum Materials our scientists and engineers believe in the power of innovation to make life better and solve critical problems facing our world. Whether its applied research into quantum materials, the development of advanced digital platforms, or creating new tools for personal health, we find our inspiration in discovering new solutions to build a better future for all. Quantum Materials is pioneering unique solutions in the area of quantum dot fabrication, quantum tagging, digital trust systems, and most recently, in the development of QMC HealthID™. Our team comprises experts in the areas of quantum materials, nanotechnology, health diagnostics, therapeutic health, digital platforms, advanced logistics, and anti-counterfeiting. As a company, we believe in collaboration. We find that innovation begins with the spark of a new insight that is rigorously pursued in a collegial and interdisciplinary environment. Bringing breakthrough ideas to life and forging new solutions inspires our work. For more information, visit Quantum Materials Corp at www.quantummaterialscorp.com
About QMC HealthID Inc.
QMC HealthID Inc., a wholly owned subsidiary of Quantum Materials Corp. (OTC Bulletin Board: QTMM), leverages its QMC technologies to address global health challenges spurred by current and future pandemics. The QMC HealthID™ management platform and mobile app authenticates the process of infectious disease testing and gives the individual control over the data they share and their personal health status. Virtually any current Covid-19 point of care or laboratory-based diagnostic test, including Innova Medical Group’s, SARS-CoV-2 Antigen Rapid Qualitative Test, can be implemented in the QMC HealthID™ testing and reporting solution. These tests along with the mobile app are designed to test for COVID-19, with benefit towards helping people get safely and securely back to work, school, travel, events and living. For more information, please visit www.qmchealthid.com.
About PopupRx
EverydayRx Is an Austin, Texas-based Pharmacy Experience Management Company focused on delivering uniquely crafted digital pharmacy experience solutions which enable pharmacies and their pharmacists to create safe and secure digital experiences which enhance how patients acquire prescriptions and receive pharmacy services at or beyond the traditional pharmacy counter to the home counter.
QMC HealthID™, Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although QMC HealthID’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of QMC HealthID™, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, QMC HealthID’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly, and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. Other than as required by applicable law, QMC HealthID™ does not undertake any obligation to update or revise any forward-looking information or statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005294/en/
And if it came by April 30th? What's the difference? What does it change?
Nothing.
May take until end of April, but better late than never.
Correct. But it does show that states are warming up to rapid tests that do not require a doctor or prescription.
What would be the excuse if it goes beyond .20 and stays above that?
Understood. That would be an interesting development if true.
Are you implying that Innova and QMC perhaps created Bella HealthAI?
Just trying to see that I am following correctly.
I'm not sure to be honest.
Bella HealthAI is owned/created by LivePerson Inc. Wouldn't Bella be a separate technology owned by a separate entity?
It also depends on what the definition of "test assistance" means. QMC HealthID, as a test registration and passport app, can be considered as a "test assistance" app, couldn't it?
Ah. Are you implying that perhaps Bella HealthAI and QMC HealthID would be bundled together as one application? Such as a partnership between QMC and Live Person Inc?
If I am understanding your post correctly, my response would be that both QMC HealthID and Bella HealthAI would work in tandem with each other.
This is what I speculate, since both apps are different in their purpose: One will provide guidance on how to administer the test (Bella HealthAI), while the other will record the test and acts as a health pass (QMC HealthID).
The generation of the Health pass is the only question that I have. In my opinion, I can only assume it'll be QMC HealthID, with their current partnerships and distribution agreements with Innova and Pasaca.
Perhaps we'll see something from QMC that connects them with Bella's services. We should know in the next couple of weeks.
Per the PR, Bella AI is strictly an administrative aid AP.
The digital health pass does not appear to be party of the Bella platform, but it also does not state that it is QMC's. Because Innova have a distribution agreement with QMC HealthID and Pasaca, I would think they are using QMC HealthID.
What is good is that this program will help get Innova on the US market, which will benefit Quantum Materials.
Bella Health IA, is something completely different than QMC HealthID.
The Bella Health AI sole purpose is to help administer the test. It provides visual aids to allow people to take the test correctly. This is expected to improve the accuracy results for approval in the US by the FDA.
QMC HealthID allow you to register your test and acts as a digital health pass. They would work in tandem.
Sure.
Put another on QTMM and make double.
That is the new AI app that helps user's with administering the test properly.
Hopefully this will help push the FDA for home use in the US if this program is successful.
Citi Debuts Rapid At-Home Covid Tests to Branch Workers, Traders
https://www.google.com/amp/s/www.bloombergquint.com/amp/onweb/citi-debuts-rapid-at-home-covid-tests-to-branch-workers-traders
LivePerson And Innova Medical Group Announce Partnership For AI-powered, At-home COVID-19 Rapid Testing
https://www.prnewswire.com/news-releases/liveperson-and-innova-medical-group-announce-partnership-for-ai-powered-at-home-covid-19-rapid-testing-301244299.html
I think there are other points in that article besides the singular one you pointed out.
But yes, I would not expect him to say "Testing won't work. Close up shop".
‘We can mass test the UK out of Covid lockdowns,’ says Innova
https://www.thetimes.co.uk/article/we-can-mass-test-the-uk-out-of-covid-lockdowns-says-innova-qstb5h363
REGISTRATION RIGHTS AGREEMENT
https://www.sec.gov/Archives/edgar/data/1403570/000149315221002306/ex10-3.htm
"(k) The Company shall use its best efforts to (i) cause the Initial Public Date to occur on or before March 31, 2021, (ii) cause the Common Stock to be listed on the New York Stock Exchange or on the NASDAQ Stock Market and to remain eligible for trading thereon...."
REGISTRATION RIGHTS AGREEMENT
https://www.sec.gov/Archives/edgar/data/1403570/000149315221002306/ex10-3.htm
"(k) The Company shall use its best efforts to (i) cause the Initial Public Date to occur on or before March 31, 2021, (ii) cause the Common Stock to be listed on the New York Stock Exchange or on the NASDAQ Stock Market and to remain eligible for trading thereon...."
While "anything" is possible, Pasaca wouldn't require QMC to go public on NYSE or NASDAQ and to remain eligible for trading thereon if Pasaca intended to take QMC private. It would be the completely opposite of the registration rights agreement.
Dr. Malan, M.D. joins As Chief Medical Officer.
Innova Medical Group Announces New Chairman and Chief Medical Officer
Expanded leadership team will continue to grow the company's capabilities for COVID-19 testing and other innovative healthcare technologies
PASADENA, Calif., Mar. 1, 2021 /PRNewswire/ -- Innova Medical Group, Inc., the world's largest manufacturer of rapid antigen test kits and leader in COVID-19 testing solutions globally, announced today the appointment of Sean Rogers as Chairman of Innova Medical Group, and Todd Malan, M.D., as Innova's Chief Medical Officer. The two seasoned leaders will be valuable additions to Innova's continued growth in screening and diagnostic test production and distribution, as well as its expanding partnerships with health authorities around the world to help break the COVID-19 chain of transmission and end the deadly pandemic through widespread testing for home screening and clinical diagnostics.
"Since the beginning of the pandemic, Innova's rapid and accessible antigen tests have proven to be a critical tool in comprehensive testing regimes to contain COVID-19 and save lives," said Sean Rogers, newly appointed Chairman of Innova Medical Group. "I'm honored to be joining the leadership team of this growing company at such a crucial time for global health, as we fight to combat further spread of the virus and get people back to work and normal life."
Rogers comes to Innova from Citigroup, where he was most recently the Global Head of Technology Strategy and Solutions. In this role, Rogers created partnerships between established companies and promising startups, and shepherded many high-profile technology companies through capital formation, as well as mergers and acquisitions. As diagnostic medicine moves toward incorporating artificial intelligence and machine learning, Rogers' experience in the field will assure that Innova continues to deliver sophisticated and equitable diagnostic tests. Rogers has also been named Chief Executive Officer of Pasaca Capital, the parent company of Innova Medical Group.
Dr. Malan has built a long record of scientific and medical innovation, both in his most recent role as the Senior Vice President of clinical research at Quantum Material Corporation and through his specialized research in stem cell therapy and regenerative medicine. He previously served as Chief Medical Officer for iQuantum Labs, founded the investigational research for adipose derived cell therapies at the Center for Regenerative Cell Medicine, and served as Medical Director for adipose tissues services at Celebration Stem Cell Labs in Arizona. He holds board certifications from the American Board of Regenerative Medicine, the American Board of Obstetrics and Gynecology and the American Board of Cosmetic Surgery. He earned his medical degree from University of Arizona College of Medicine.
"All the challenges of the past year have demonstrated the need for simple, rapid and accessible diagnostic tests – for COVID-19 and for other diseases," said Dr. Todd Malan, Innova's new Chief Medical Officer. "Innova has established itself as a leader in manufacturing and distributing indispensable tests to nations around the world, and I'm proud to lead its medical team as we build on our expertise and capacity to help fight this global pandemic and develop additional innovative tools for healthcare in the future."
"I'm excited to welcome Sean and Todd to the Innova team," said CEO Daniel Elliott. "Our company is experiencing rapid growth and we are working non-stop to meet the needs of our clients around the world whose citizens and employees rely on our tests to stay safe and get back to work. I've got tremendous confidence that these two new Innova executives are up to the challenge."
From the looks of it, he'll be holding both positions.
Interesting development
Fully aware of that.
Let's see how things unfold.
I believe it was discussed prior that the agreement doesn't have a definitive date on Up-listing, and only one for financials.
QMC could become a "unicorn" prior to up-listing.
Or QMC can become a billion dollar company after the fact, which basically meets the same goal, just not under the "unicorn" definition.
Those photos that came along with Pasaca's case study on QMC, to me, are brand new and never before seen.
IMO it just shows that R & D continues to occur with their Quantum Dots. We'll need to wait and see what the future holds.
Quantum Materials Corp. to Accelerate Development of QMC HealthID™ and Quantum Dot Research Following Equity Investment from Pasaca Capital Inc.
The investment further strengthens the existing relationship between QMC HealthID™ and Innova Medical Group Inc., a Pasaca Capital Inc. portfolio company.
https://www.businesswire.com/news/home/20210202005387/en/Quantum-Materials-Corp.-to-Accelerate-Development-of-QMC-HealthID%E2%84%A2-and-Quantum-Dot-Research-Following-Equity-Investment-from-Pasaca-Capital-Inc.
1.
Form 8k: Entry into a Material Definitive Agreement between Quantum Materials Corp and Pasaca Capital
https://www.sec.gov/Archives/edgar/data/1403570/000149315221002306/form8-k.htm
Securities Purchasing and Financing Agreement
https://www.sec.gov/Archives/edgar/data/1403570/000149315221002306/ex10-1.htm
SECURED CONVERTIBLE PROMISSORY NOTE
https://www.sec.gov/Archives/edgar/data/1403570/000149315221002306/ex10-2.htm
Registration Rights Agreement
https://www.sec.gov/Archives/edgar/data/1403570/000149315221002306/ex10-3.htm
Distribution Agreement
https://www.sec.gov/Archives/edgar/data/1403570/000149315221002306/ex10-4.htm
2.
Form 8k: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
https://www.sec.gov/Archives/edgar/data/1403570/000149315221003266/form8-k.htm
Email dated February 4, 2021 received from Dr. Less Paull. (Filed herewith.)
https://www.sec.gov/Archives/edgar/data/1403570/000149315221003266/ex99-1.htm
3.
Form 8k Press Release: The QMC HealthID solution will be offered as part of Tried & Tested growing portfolio of test kits, allowing for fast and accurate demonstration of individual’s health status.
https://www.sec.gov/Archives/edgar/data/1403570/000149315221004586/form8-k.htm
Also on Pasaca's website:
Pasaca appears to have updated their website. QTMM is shown as one of their portfolio companies:
https://pasacacapital.com/
Pasaca's website also has a case study on Quantum Materials, going over it's overview, the challenges, and Pasaca's personal impact:
https://pasacacapital.com/case-study/quantum-materials/
Willing to bet we'll hear more in the future
Interesting nugget of information on today's recent PR:
https://www.businesswire.com/news/home/20210223005230/en/
I hope you keep that same energy if it recovers ;)
QMC HealthID News
QMC HealthID Partners with Tried & Tested to Support COVID-19 Diagnostic Testing in the UK
The QMC HealthID solution will be offered as part of Tried & Tested growing portfolio of test kits, allowing for fast and accurate demonstration of individual’s health status.
QMC HealthID, a wholly owned subsidiary of Quantum Materials Corp, today announced that it has partnered with Tried & Tested COVID-19 testing services. The QMC HealthID service will allow companies and individuals to see and select a particular COVID-19 test kit and record the test results.
Tried & Tested specializes in the development and implementation of Covid-19 test programs, including rapid Antigen, IgM/IgG Antibody, and PCR tests. The company has experience with the rollout of testing programs at the national, regional and metropolitan levels across the public and private sectors. The QMC HealthID platform is expected to add new capabilities to the Tried and Tested portfolio of test offerings.
“We look forward to introducing QMC HealthID as part of a multi-layered solution to reduce the impact of Covid and hopefully help us on our way out of the pandemic,” said Charles Palmer, Director of Tried & Tested. “When we were introduced to the QMC team, we found likeminded individuals who wanted to create a fast, affordable, scalable and disruptive solution which made full use of maximizing the latest technology.“
QMC HealthID plans to leverage Tried and Tested knowledge and experience in the UK marketplace. Tried and Tested’s network of relationships adds to QMC HealthID’s ecosystem of test providers that includes Innova Medical Group, MicroGen Diagnostics, and Osang Healthcare. Tried and Tested brings additional professional capabilities related to test protocols and a network of registered healthcare staff for test administration.
“As our world shifts its focus on getting back to life, we see promise in the partnership with Tried & Tested,” said Stephen B. Squires, CEO of Quantum Materials Corp. “Joining forces with Tried & Tested accelerates our plan to offer QMC HealthID in the UK. We look forward to working with the Tried & Tested team, a highly experienced and innovative group, who have been deeply involved in the provision of scale Covid-19 testing programs. We could not have found a more capable partner.”
https://www.businesswire.com/news/home/20210223005230/en/
Per the 8k, they have an obligation to be Current by March 31st.
Recommend reading the last few 8K's
QMC signed a deal with Pasaca Capital ($9 Billion company) to develop a finished product for Innova Medical Group, the largest distributor of Covid tests in the UK.
Finished product being presumably QMC Health ID.
This deal will require QMC to be up to date on filings no later than March 31st (on a best effort basis) with an up-listing to either NYSE or NASDAQ sometime thereafter.
This does require the AS to increase to 1.8B shares, since Pasaca will be taking over 51% of the company and adding 3 board members.
My assumption is that any potential revenues that come forth from the Pasaca/Innova deal will further accelerate R&D on their Q Dots, Anti-Counterfeiting, and others.
That is what I am mostly invested for, athough QMC Health ID is a nice bonus short term.